MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured significant new funding from Oberland Capital to advance two gene therapies toward commercialization.
📍 Where it landed
MeiraGTx secured financing through royalty agreements and equity to support the commercialization of its gene therapies and the retirement of existing debt. The company also outlined plans for a BLA filing in 2027 following data updates for its xerostomia program.
Coverage of the funding deal quieted after market analysts reiterated their stock ratings.
Epilogue added 18d ago, after coverage quieted.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
MeiraGTx has obtained up to $400 million from Oberland Capital, comprising $375 million in royalty financing and $10 million in equity. The funding is intended to support the commercialization of two gene therapies and has allowed the company to retire Perceptive debt.
Coverage from Fierce Biotech, TradingView, and Simply Wall St emphasizes the scale of the cash infusion, noting that the stock rose 8.5% following the announcement. Wainwright has reiterated its stock rating for the company in response to the financing deal.
Future catalysts include the BLA filing for AAV2-hAQP1 for xerostomia, which is expected in the first half of 2027, as well as the Bota-Vec acquisition according to Seeking Alpha.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 18d ago.
The reporting (5)
- MeiraGTx Secures Up To $375 Million Royalty Financing, Adds $10 Million Equity, Retires Perceptive Debt TradingView · 21d ago
- Exclusive BAC Article: MeiraGTx; AAV2-hAQP1 Q2 207 Data Xerostomia, BLA Filing 1st Half 2027, Bota-Vec Acquisition, Oberland Capital Cash Infusion, And Catalysts (NASDAQ:MGTX) Seeking Alpha · 21d ago
- MeiraGTx Holdings (MGTX) Is Up 8.5% After Securing US$425M In New Funding Pathways simplywall.st · 21d ago
- H.C. Wainwright reiterates MeiraGTx stock rating on financing deal Investing.com · 21d ago
- MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization Fierce Biotech · 21d ago
The obvious questions
How much funding did MeiraGTx secure?
Funding reports vary slightly, with Fierce Biotech citing $400 million and Simply Wall St mentioning $425 million in new funding pathways.
What is the purpose of the Oberland Capital investment?
The funds are intended to help bring two gene therapies to commercialization.
When is the BLA filing for AAV2-hAQP1 expected?
According to Seeking Alpha, the BLA filing for xerostomia is expected in the first half of 2027.
Topics
Related trends
Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients
8 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Breathalyser can tell if you are burning fat from a single exhalation
6 news sources are covering this Technology story right now — Archynetys is tracking how fast it spreads.
Engineered enzyme erases a stubborn mark of aging by up to 70% in human tissue samples
Engineered enzymes are being utilized to reverse molecular protein damage in human tissue samples, potentially addressing a biological marker of aging.
MIT Scientists Grew Artificial Blood Vessels In The Lab Using Magnets
MIT engineers have developed a method to grow and redirect artificial blood vessels using magnetic fields and mechanical stretching.
Boston Children’s and the Broad Institute partner on new center for rare genetic diseases
Three major institutions have launched the Center for Therapeutic Genetics to develop medicines for rare and ultra-rare genetic diseases.
Wooly Mammoth startup Colossal seeking at least $20B valuation
De-extinction startup Colossal Biosciences is reportedly seeking a valuation between $20 billion and $30 billion in a new funding round.